Sonic Incytes key facts
as of Oct 2026- Developer of an AI-guided ultrasound elastography device designed to assess and monitor chronic liver diseases at the point of care.
- Sonic Incytes is valued at approximately $80.0M as of Oct 2026 (last reported valuation).
- It has raised $39.4M; the latest was Later Stage VC ($25.0M) in Oct 2025.
- Notable investors include Creative Destruction Lab, Mana Ventures, MedTech Innovator, Gaingels, Life Sciences BC — 27 tracked in total.
- Status: Privately Held (backing).
Sonic Incytes's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 27 names
- ·Watch Sonic Incytes: the Monday email on marks, rounds and moves
Sonic Incytes funding rounds
No funding rounds for Sonic Incytes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Sonic Incytes
27+Sonic Incytes valuation
Sonic Incytes's last reported valuation was $80 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Sonic Incytes investors
27 investors are on record for Sonic Incytes, including Creative Destruction Lab, Mana Ventures, MedTech Innovator and Gaingels.
About Sonic Incytes
Developer of an AI-guided ultrasound elastography device designed to assess and monitor chronic liver diseases at the point of care. The company's devices utilize artificial intelligence to offer deeper measurements and larger tissue samples, single probes without recalibrations, and guidance to check for liver stiffness, attenuation, and velacur-determined fat fraction, enabling healthcare providers to perform non-invasive liver assessments efficiently and support accurate clinical decision making during patient visits.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2016
- Employees
- 41
- Website
- sonicincytes.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.